MRD Leukemia Panel - (CLPD) by Flow Cytometry, EDTA Bone Marrow**

Flow for Lymphoma/CLPD/Lymphoma MRD is a diagnostic test that has clinical utility in the assessment of minimal residual disease (MRD) in lymphoma and chronic lymphoproliferative disorders (CLPD). MRD refers to the small number of cancer cells that remain in the body after treatment. This test utilizes flow cytometry, a technique that employs fluorescently labeled antibodies, to analyze and quantify these residual cancer cells in the bone marrow, peripheral blood, or lymph nodes. By detecting and monitoring MRD, healthcare professionals can assess treatment response, predict relapse, and guide further therapeutic interventions. The Flow for Lymphoma/CLPD/Lymphoma MRD test plays a crucial role in the management of lymphoma and CLPD, providing valuable information for treatment decisions, risk stratification, and monitoring of disease progression. It aims to achieve and maintain minimal levels of residual disease, ultimately optimizing patient outcomes and improving long-term survival.